



BIOGENERATION
VENTURES



THUJA CAPITAL
healthcare investors

PRESS RELEASE

September 12th, 2008

Bioceros B.V. closes first financing round

Utrecht, The Netherlands, September 12th, 2008 – Bioceros B.V. announced today the closure of its first financing round. The round was co-led by BioGeneration Ventures and Thuja Capital. Existing corporate shareholders Forbion Capital Partners and Nodens B.V. also participated in this round.

Bioceros B.V. was established in 2003 and provides services regarding producer cell line generation, small-scale antibody manufacturing (non-GMP) and development of cell-based immunological research assays. Furthermore, Bioceros offers advice regarding pre-clinical animal proof-of-concept and safety studies. The skills and competences of the Bioceros team provide customers crucial and valuable support, especially in the early stages of protein-based drug development.

The company collaborates with various key industrial partners such as Crucell. Over the last four years Bioceros has been able to create a strong and sustainable turnover, and targets to broaden its client base in the near future.

The new financing will enable Bioceros to in-license and develop proprietary antibodies and proteins with a focus on inflammation and oncology, fitting its immunological competences.

Dr. Bram Bout, CEO of Bioceros B.V. said: “We are extremely pleased with the support of BioGeneration Ventures and Thuja Capital. This financing round allows us to leverage the value of Bioceros by building our own product pipeline”.

“We strongly believe in the high quality of the Bioceros management team”, says Edward van Wezel, managing partner at BioGeneration Ventures. “The management team has an excellent industrial and scientific track record in the development of therapeutic proteins that will be very important for the successful further growth of the company”.

Dr. Michel Briejer, investment director at Thuja Capital: “Thuja is pleased with this investment. Bioceros has access to state-of-the-art cell line generation and cell-based immunological assay capabilities and sound relationships with strong industrial partners that will enable the company to optimally serve its clients”.

Edward van Wezel and Michel Briejer will join the Board of Directors of Bioceros B.V.

About Biogeneration Ventures - BioGeneration Ventures invests in Dutch Life Sciences companies. The team of BioGeneration is specialized in the evaluation of new technologies and in the management of start-up companies. BioGeneration Ventures was co-founded by the Netherlands Genomics Initiative (NGI), NWO, the holding of the University of Leiden, and ABN-AMRO Capital. BioGeneration closely cooperates with Forbion Capital Partners (www.biogenerationventures.com).

About Thuja Capital - Thuja Capital Healthcare Fund (TCHF) is a healthcare dedicated venture capital fund structured to invest in healthcare (life science) innovations with a focus on

biopharmaceuticals and medical devices. The prime focus of TCHF is on privately held early-stage life science companies located in the Benelux.

TCHF is managed by Thuja Capital; Thuja Capital's team have a long and successful track record in life science investments and aims to help their portfolio companies to strengthen and grow their businesses. Furthermore, Thuja Capital is the exclusive manager of AlInvest Partners' portfolio of early stage life science companies (www.thujacapital.com).

Contact: Bioceros B.V.
Remco Brandt, COO
T: +31 30 253 7910
E: r.brandt@bioceros.com
W: www.bioceros.com

BioGeneration Ventures
Edward van Wezel
T: +31 35 699 3000
E: info@biogenerationventures.com
W: www.biogenerationventures.com

Thuja Capital
Michel Briejer, PhD
T: +31 30 253 3849
E: michel.briejer@thujacapital.com
W: www.thujacapital.com